Galantamine is one of the acetylcholinesterase inhibitors (AChEIs) that have been approved as the main treatment for mild to moderate Alzheimer’s disease (AD) (Lanctot et al., 2003; Pirttila et al., 2004; Wilcock, Lilienfeld & Gaens, 2000), which can inhibit enzymes from degrading acetylcholine. Here, ACHE is linked to Alzheimer disease.